Industry news that matters to you.  Learn more

Archives for May 2012

QLIDA Diagnostics Developing a Mobile Cardiac Biomarker Testing Device

A spinout of Drexel University called QLIDA Diagnostics is developing a mobile cardiac biomarker testing device for use in emergency rooms to rapidly determine whether someone is having a heart attack.

Navidea Biopharmaceuticals Announces Participation in Alzheimer’s Disease Scientific Meetings

Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB), a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Dr. Thomas Tulip, Navidea’s EVP and Chief Business Officer, was invited to present at two Alzheimer’s Disease (AD) conferences: Alzheimer’s Disease Neuroimaging Initiative (ADNI) Private Partner Scientific Board meeting and the German Nuclear Medicine Convention. Focused on Navidea’s AZD4694 radiopharmaceutical imaging biomarker for the detection of cerebral amyloid in Alzheimer’s disease (AD) patients, Dr. Tulip’s presentations highlighted AZD4694 background, status and strong attributes, such as high sensitivity and low non-target accumulation. These and other characteristics of the agent appear to make it an excellent candidate as a biomarker to facilitate enhanced therapeutic drug development.

BGI Announces Cloud-based DNA Sequencing Service Powered by NVIDIA GPUs

The technology company NVIDIA, best known for its graphics processing units (GPUs), recently announced that BGI is launching a service that will enable researchers worldwide to perform affordable next-generation sequencing (NGS) bioinformatics analysis in the cloud.

Celgene Corporation and LLS-partner Epizyme Announce Deal That Will Help Advance Therapy for Mixed Lineage Leukemia Patients

Thanks to funding from The Leukemia & Lymphoma Society (LLS), Epizyme has been advancing DOT1L, a targeted histone methyltransferase inhibitor (HMTi) as a personalized therapeutic for patients with mixed lineage leukemia (MLL).